TherapeuticsMD, Inc. TXMD · Stock Open TherapeuticsMD, Inc. in new tab
TherapeuticsMD, Inc. Analysis (TXMD)
Is TherapeuticsMD, Inc. a good investment? TherapeuticsMD, Inc. (TXMD) is currently trading at 2.28 USD.
In terms of valuation, the stock trades at a P/E ratio of 207.00. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: TherapeuticsMD, Inc. is expected to release its next earnings report on Nov. 17, 2026. The market consensus estimate for Forward EPS is 0.35.
Investor FAQ
Does TherapeuticsMD, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is TherapeuticsMD, Inc.?
TherapeuticsMD, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 17, 2026. The company currently has a trailing EPS of -0.03.
Company Profile
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names. It has a license agreement with Mayne Pharma Group Limited. The company sells its products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
| Split Date | Split Ratio to 1 |
|---|---|
| July 27, 2009 | 3:1 |
| Oct. 3, 2011 | 1:100 |
| May 9, 2022 | 1:50 |
Community Discussion